

# **Clinical Practice Guideline: Management of Non Small Cell Lung Cancer, Small Cell Lung Cancer**

## **Clinical Practice Guideline**

**Condition:** Non Small Cell Lung Cancer, Small Cell Lung Cancer

**Target Population:** Clinical trial participants (n=80)

**Evidence Level:** Grade C

**Last Updated:** November 2022

## **Treatment Recommendations**

## **Clinical Evidence Summary**

Current evidence supports the use of established treatment protocols for Non Small Cell Lung Cancer, Small Cell Lung Cancer. Clinical trials have demonstrated efficacy with Investigational use.

Contraindications include Per trial protocol. Clinicians should monitor for As reported in trial monitoring.

# Detailed Clinical Management

## Diagnostic Criteria

Diagnosis of Non Small Cell Lung Cancer, Small Cell Lung Cancer should be based on clinical presentation, laboratory findings, and imaging studies as appropriate. Consider differential diagnoses and comorbid conditions. Key diagnostic features include: • Clinical symptoms consistent with Non Small Cell Lung Cancer, Small Cell Lung Cancer • Laboratory abnormalities as expected • Imaging findings supportive of diagnosis • Response to therapeutic interventions

## Therapeutic Monitoring

Ongoing monitoring is essential for optimal patient outcomes. Current protocols recommend Standard study precautions. Patients should be assessed regularly for: • Treatment efficacy • Adverse effects • Disease progression • Need for therapy modification